Advocate Health Care, the largest integrated health care system in the state of Illinois, USA, and GE Healthcare have announced a joint effort to help further reduce radiation dose in computed tomography (CT).
Is one device more effective than the other, with respect to radioembolization for hepatocellular carcinoma with or without portal vein thrombosis, metastatic colorectal cancer and neuroendocrine tumours? Examining the medical literature, the answer is “no”, Robert Lewandowski, Chicago, USA, said.
A recent clinical investigation from The Netherlands, published in the journal Cardiovascular and Interventional Radiology (CVIR), has revealed that the use of a validated comprehensive patient safety checklist in interventional radiology in a tertiary referral centre led to a significant decrease in process deviations and procedure postponements.
Surefire Medical has received CE mark approval for its Surefire Infusion System, a next generation device for chemo- and radioembolization procedures. The company has announced that the launch of this product will be effective immediately.
Patients with uncontrolled renovascular hypertension saw a significant improvement in their blood pressure with renal artery stenting. The multicentre HERCULES trial, evaluating the safety and effectiveness of the RX Herculink Elite Stent (Abbott Vascular), found that patients with higher blood pressure levels at baseline had the most dramatic reduction in blood pressure following intervention. Results have been published in the September issue of Catheterization and Cardiovascular Interventions.
“We need to be very careful not to kill a promising technology with incorrect patient selection,” Pierre-François Plouin, Paris, France, warned delegates at the EuroPCR Great Debate 2012 on renal denervation. In the debate, Plouin and four other experts in interventional cardiology, interventional radiology and nephrology agreed that identifying the right group of patients is key for the future of the technique. The group also discussed patient compliance to medical therapy, clinical data associated with the procedure and the balance between risk and benefit.
The US Food and Drug Administration (FDA) has granted 510(k) clearance to AngioDynamics for its BioFlo peripherally inserted central catheters (PICCs) with Endexo technology designed to reduce the accumulation of catheter-related thrombus on, and in, the catheter.
Results from the EnligHTN I trial have shown that the EnligHTN renal denervation system (St Jude Medical) is safe and effective for the treatment of resistant hypertension. Data released during the ESC Congress 2012 demonstrated that on average patients with resistant hypertension experienced a rapid systolic blood pressure reduction of 28 mmHg points after 30 days that remained stable with a reduction of 27 mmHg points three months after treatment.
On 29 August, the UK’s National Institute for Health and Clinical Excelence (NICE) published guidance supporting the use of contrast-enhanced ultrasound with SonoVue (Bracco) to diagnose liver cancer.
Results from the EnligHTN I trial have shown that the EnligHTN renal denervation system (St Jude Medical) is safe and effective for the treatment of resistant hypertension. Data released during the ESC Congress 2012 demonstrated that on average patients with resistant hypertension experienced a rapid systolic blood pressure reduction of 28 mmHg points after 30 days that remained stable with a reduction of 27 mmHg points three months after treatment.
Medtronic announced new results from SYMPLICITY HTN-2, the only randomised clinical trial investigating safety and efficacy of renal denervation. The 18-month data presented for the first time at the European Society of Cardiology (ESC) Congress on 26 August 2012 showed that the Symplicity system continues to provide superior and sustained blood pressure reduction in patients with treatment-resistant hypertension. The safety of renal denervation with the Symplicity system was also maintained at 18 months, with no device-related serious adverse events and no newly reported vascular complications from 12–18 months.
Toshiba America Medical Systems has received FDA clearance for its Aquilion RXL Edition CT system. The Aquilion RXL reconstructs images faster and includes the latest dose reduction technologies, providing faster, safer information to physicians and patients.
The System, a collaborative film by the British Society of Interventional Radiology (BSIR) and the Health Foundation, an independent charity, traces the way in which a combination of factors are shown to converge during a biliary intervention procedure carried out on a patient.
At the GEST 2012 US meeting in New York, USA, James B Spies, Georgetown University Hospital, Washington DC, USA, outlined the basic properties of spherical particles.
David N Siegel, chief, Division of Vascular and Interventional Radiology, Northshore Island Jewish Health System, New York, USA, told delegates at GEST 2012 US that interventional radiologists must take primary responsibility for the initial evaluation and management of post-uterine fibroid embolization patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos